$4.27
4.37% today
Nasdaq, Nov 04, 09:19 pm CET
ISIN
US8776191061
Symbol
TSHA

Taysha Gene Therapies Inc Stock price

$4.46
-0.30 6.30% 1M
+2.00 81.30% 6M
+2.73 157.80% YTD
+3.12 232.84% 1Y
+2.51 128.72% 3Y
-16.73 78.95% 5Y
-15.54 77.70% 10Y
-15.54 77.70% 20Y
Nasdaq, Closing price Mon, Nov 03 2025
-0.50 10.08%
ISIN
US8776191061
Symbol
TSHA
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$945.5m
Net debt
positive
Cash
$312.8m
Shares outstanding
272.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
150.2 | 152.6
EV/Sales
116.7 | 118.6
EV/FCF
negative
P/B
4.9
Financial Health
Equity Ratio
44.6%
Return on Equity
-124.9%
ROCE
-30.5%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$8.1m | $8.0m
EBITDA
$-92.9m | $-109.2m
EBIT
$-94.0m | $-107.8m
Net Income
$-92.7m | $-97.6m
Free Cash Flow
$-82.5m
Growth (TTM | estimate)
Revenue
-37.1% | -4.3%
EBITDA
-18.8% | -27.8%
EBIT
-18.2% | -24.4%
Net Income
18.9% | -9.3%
Free Cash Flow
-9.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,146.5% | -1,369.4%
EBIT
-1,160.8%
Net
-1,145.0% | -1,224.2%
Free Cash Flow
-1,019.2%
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
17.2%
Employees
73
Rev per Employee
$110.0k
Show more

Is Taysha Gene Therapies Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.

Taysha Gene Therapies Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Taysha Gene Therapies Inc forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Taysha Gene Therapies Inc forecast:

Buy
95%
Hold
5%

Financial data from Taysha Gene Therapies Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
8.10 8.10
37% 37%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 31 31
5% 5%
386%
- Research and Development Expense 66 66
10% 10%
815%
-93 -93
19% 19%
-1,146%
- Depreciation and Amortization 1.16 1.16
14% 14%
14%
EBIT (Operating Income) EBIT -94 -94
18% 18%
-1,161%
Net Profit -93 -93
19% 19%
-1,145%

In millions USD.

Don't miss a Thing! We will send you all news about Taysha Gene Therapies Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Taysha Gene Therapies Inc Stock News

Neutral
Seeking Alpha
about one hour ago
Taysha Gene Therapies, Inc. ( TSHA ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Hayleigh Collins - Director of Corporate Communications & Investor Relations Sean Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development and Director Kamran Alam - CFO & Corporate Secretary Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co...
Neutral
GlobeNewsWire
about 9 hours ago
TSHA-102 granted Breakthrough Therapy designation by FDA Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including 6-month interim analysis that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials showing an unprecedented response rate Dosing of first patient in REVEAL pivotal trial scheduled for Q...
Neutral
GlobeNewsWire
7 days ago
DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the third quarter ended September 30, 2025, and ...
More Taysha Gene Therapies Inc News

Company Profile

Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.

Head office United States
CEO Sean Nolan
Employees 73
Founded 2019
Website tayshagtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today